A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0501. Issue 2 (February 2015) - Nogami, Naoyuki
Highlights A S-1-based chemo-radiation was effective and safe in stage III NSCLC. The median progression-free survival time was 9.3 months. The median survival time was 31.3 months. Toxicities were generally mild except for febrile neutropenia and pneumonitis.